ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.
Colorectal Cancer
OTHER: ALK Inhibitor
Objective Respone Rate(ORR), Evaluation of tumor burden based on RECIST criteria every 2 month., up to 36months
This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.